Research ArticleClinical Studies

Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma

HIROKI ISHIHARA, TOSHIO TAKAGI, TSUNENORI KONDO, HIRONORI FUKUDA, HIDEKAZU TACHIBANA, KAZUHIKO YOSHIDA, JUNPEI IIZUKA, MASAYOSHI OKUMI, HIDEKI ISHIDA and KAZUNARI TANABE
In Vivo May 2020, 34 (3) 1541-1546; DOI: https://doi.org/10.21873/invivo.11943

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Waterfall plot for maximum changes of targeted lesions from baseline. *Patient whose best tumor response was diagnosed as progressive disease based on the RECIST v.1.1. because of the appearance of new lesions. PD: Progressive disease; SD: stable disease; PR: partial response.

  • Figure 2.
    Figure 2.

    Progression-free and overall survival after the initiation of axitinib. CI: Confidence interval; N.R.: not reached; PFS: progression-free survival; OS: overall survival.

  • Figure 3.
    Figure 3.

    Timing and duration of distinct systemic therapies in first-line tyrosine kinase inhibitors, second-line nivolumab, and third-line axitinib.

Tables

  • Table I.
  • Table II.
  • Table III.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma
HIROKI ISHIHARA, TOSHIO TAKAGI, TSUNENORI KONDO, HIRONORI FUKUDA, HIDEKAZU TACHIBANA, KAZUHIKO YOSHIDA, JUNPEI IIZUKA, MASAYOSHI OKUMI, HIDEKI ISHIDA, KAZUNARI TANABE
In Vivo May 2020, 34 (3) 1541-1546; DOI: 10.21873/invivo.11943
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords